ESPE Abstracts (2015) 84 P-3-941

Decrease of Small Dense LDL and Lipoprotein-Associated Phospholipase A2 due to Human GH Treatment in Short Children with GH Deficiency and Small for Gestational Age Status

Andreas Krebsa, Thomas Kratzina, Jürgen Doerfera, Karl Winklerb, Michael Wurma, Natascha van der Werf-Grohmanna, Alexandra Krausea & Karl Otfried Schwaba


aDepartment of Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany; bDepartment of Clinical Chemistry, University Medical Center, Freiburg, Germany.


Objectives: GH deficiency (GHD) and small for gestational age (SGA) status are associated with cardiovascular risks. We therefore investigated antiatherogenic effects of GH.

Methods: Subfractions of LDL and HDL, lipoprotein-associated phospholipase A2 (Lp-PLA2), and high-sensitivity C-reactive protein (hsCRP) were measured at baseline, after 8 and 52 weeks of GH treatment in 51 short children born SGA (n=33) or with GHD (n=18).

Results: For the overall group, we found post-treatment reductions of LDL cholesterol (P=0.016), small-dense LDL cholesterol (P<0.001), Lp-PLA2 (P<0.001), and hsCRP (P=0.005), but increases of HDL2a cholesterol (P=0.025). SGA children showed reductions of small-dense LDL cholesterol (P=0.02), Lp-PLA2 (P=0.002), hsCRP (P=0.037) and increases of HDL2a cholesterol (P=0.004). GH deficient children had non-significant decreases of small-dense LDL cholesterol, Lp-PLA2, hsCRP and increases of HDL2a cholesterol.

Conclusions: Children with GHD or born SGA may benefit from GH treatment by growth acceleration and simultaneous reduction of their latent cardiovascular long-term risk.